184
Views
3
CrossRef citations to date
0
Altmetric
Original Article

Magnesium isoglycyrrhizinate attenuates D-galactosamine/lipopolysaccharides induced acute liver injury of rat via regulation of the p38-MAPK and NF-κB signaling pathways

, &
Pages 262-267 | Received 22 Oct 2017, Accepted 12 Feb 2018, Published online: 28 Feb 2018

References

  • Bernal W, Auzinger G, Dhawan A, et al. Acute liver failure. Lancet 2010;376:190–201.
  • Lv YY, Jin Y, Han GZ, et al. Ursolic acid suppresses IL-6 induced C-reactive protein expression in HepG2 and protects HUVECs from injury induced by CRP. Eur J Pharm Sci 2012;45:190–194.
  • Jalan R, Olde Damink SW, Hayes PC, et al. Pathogenesis of intracranial hypertension in acute liver failure: inflammation, ammonia and cerebral blood flow. J Hepatol 2012;45:613–620.
  • Newsome PN, Plevris JN, Nelson LJ, et al. Animal models of fulminant hepatic failure: a critical evaluation. Liver Transpl 2000;6:21–31.
  • Li X, Gou C, Yang H, et al. Echinacoside ameliorates D-galactosamine plus lipopolysaccharideinduced acute liver injury in mice via inhibition of apoptosis and inflammation. Scand J Gastroenterol 2014;49:993–1000.
  • Xiong Q, Hase K, Tezuka Y, et al. Acteoside inhibits apoptosis in D-galactosamine and lipopolysaccharide-induced liver injury. Life Sci 1999;65:421–430.
  • Yan R, Li Y, Zhang L, et al. Augmenter of liver regeneration attenuates inflammation of renal ischemia/reperfusion injury through the NF-kappa B pathway in rats. Int Urol Nephrol 2015;47:861–868.
  • Pasparakis M. Regulation of tissue homeostasis by NF-kappaB signalling: implications for inflammatory diseases. Nat Rev Immunol 2009;9:778–788.
  • Wu Z, Han M, Chen T, et al. Acute liver failure: mechanisms of immune-mediated liver injury. Liver Int 2010;30:782–794.
  • Adams DH, Ju C, Ramaiah SK, et al. Mechanisms of immune-mediated liver injury. Toxicol Sci 2010;115:307–321.
  • Ganai AA, Khan AA, Malik ZA, et al. Genistein modulates the expression of NF-κB andMAPK(p-38 and ERK1/2), thereby attenuating D-Galactosamine induced fulminant hepatic failure in Wistar rats. Toxicol Appl Pharm 2015;283:139–146.
  • He Y, Zeng F, Liu Q, et al. Protective effect of magnesium isoglycyrrhizinate on ethanol-induced testicular injuries in mice. J Biomed Res 2010;24:153–160.
  • Sun L, Shen J, Pang X, et al. Phase I safety and pharmacokinetic study of magnesium isoglycyrrhizinate after single and multiple intravenous doses in Chinese healthy volunteers. J Clin Pharmacol 2007;47:767–773.
  • Cheng Y, Zhang J, Shang J, et al. Prevention of free fatty acid-induced hepatic lipotoxicity in HepG2 cells by magnesium isoglycyrrhizinate in vitro. Pharmacology 2009;84:183–190.
  • Huang X, Qin J, Lu S. Magnesium isoglycyrrhizinate protects hepatic L02 cells from ischemia/reperfusion induced injury. Int J Clin Exp Pathol 2014;7:4755–4764.
  • Wei W, Jing C, Guang L, Jie X. Anti-inflammatory activities of fenoterol through β-arrestin-2 and inhibition of AMPK and NF-kB activation in AICAR-induced THP-1 cells. Biomed Pharmacother 2016;84:185–190.
  • Wei W, XiaoGuang L, Jie X. Exposure to cigarette smoke downregulates β2-adrenergic receptor expression and upregulates inflammation in alveolar macrophages. Inhal Toxicol 2015;25:488–494.
  • Wei W, Yuan Z, Ming X, et al. Fenoterol inhibits LPS-induced AMPK activation and inflammatory cytokine production through β-arrestin-2 in THP-1 cell line. Biochem Biophys Res Commun 2015;526:119–123.
  • Tang G, Yang H, Zhang J, et al. Magnesium isoglycyrrhizinate inhibits inflammatory response through STAT3 pathway to protect remnant liver function. World J Gastroenterol 2015;21:12370–12380.
  • Xie C, Li X, Wu J, et al. Anti-inflammatory activity of magnesium isoglycyrrhizinate through inhibition of phospholipase A2/arachidonic acid pathway. Inflammation 2015;38:1639–1648.
  • Wei C, Yuan L, Ya Z, et al. Rosiglitazone protects rat liver against acute liver injuryassociated with the NF-kB signaling pathway. Can J Physiol Pharmacol 2016;94:28–34.
  • Yi PF, Wu YC, Dong HB, et al. Peimine impairs pro-inflammatory cytokine secretion through the inhibition of the activation of NF-κB and MAPK in LPS-induced RAW264.7 macrophages. Immunopharmacol Immunotoxicol 2013;35:567–572.
  • Dubuquoy L, Dharancy S, Nutten S, et al. Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet 2002;360:1410–1418.
  • Zhu C, Wang Q, Zhou J, et al. The mineralocorticoid receptor-p38MAPK-NFκB or ERK-Sp1 signal pathways mediate aldosterone-stimulated inflammatory and profibrotic responses in rat vascular smooth muscle cells. Acta Pharmacol Sin 2012;33:873–878.
  • Guo R, Wu K, Chen J, et al. Exogenous hydrogen sulfide protects against doxorubicin-induced inflammation and cytotoxicity by inhibiting p38MAPK/NF-κB pathway in H9c2 cardiac cells. Cell Physiolo Biochem 2013;32:1668–1680.
  • Jang J, Surh Y. AP-1 mediates beta-amyloid-induced iNOS expression in PC12 cells via the ERK2 and p38 MAPK signaling pathways. Biochem Biophys Res Commun 2005;331:1421–1428.
  • Bing L, Jian H, Bin Z. Nobiletin protects against murine l-arginine-induced acute pancreatitis in association with downregulating p38MAPK and AKT. Biomed Pharmacother 2016;81:104–110.
  • Chae HJ, Byun JO, Chae SW, et al. p38 MAPK and NF-κB on IL-6 Release in Human Gingival Fibroblasts. Immunopharmacol Immunotoxicol 2008;27:631–646.
  • Veres B, Radnai B, Gallyas F, Jr, et al. Regulation of kinase cascades and transcription factors by a poly(ADP-ribose) polymerase-1 inhibitor, 4-hydroxyquinazoline, in lipopolysaccharide-induced inflammation in mice. J Pharmacol Exp Ther 2004;310:247–255.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.